Skip to main content

Table 5 Comparative estimates of costs, QALYs, and ICERs: sensitivity analysis excluding non-responder anti-TNF costs past 24 weeks

From: Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates

  Anti-TNF user Anti-TNF non-user Increment (user vs non-user) 95% CIa
Canada
 Costs 12,405 1656 10,749 (8868, 12,789)
 QALYs 0.626 0.609 0.017 (−0.008, 0.042)
 ICER    626,459 (247,149, Dominated)
France
 Costs 12,566 1696 10,870 (9144, 12,751)
 QALYs 0.620 0.607 0.013 (−0.011, 0.036)
 ICER    857,992 (284,242, Dominated)
UK
 Costs 12,973 737 12,236 (8981, 15,769)
 QALYs 0.627 0.606 0.021 (−0.015, 0.059)
 ICER    578,899 (187,442, Dominated)
Germany
 Costs 12,321 1682 10,640 −877,112,728
 QALYs 0.642 0.617 0.025 (0.001, 0.050)
 ICER    422,568 (206,749, 14,587,057)
Hong Kong
 Costs 11,935 891 11,044 (7243, 15,470)
 QALYs 0.619 0.586 0.033 (−0.011, 0.076)
 ICER    335,418 (124,073, Dominated)
  1. aLower bound = 2.5 th, upper bound = 97.5 th percentile of bootstrapped distribution